Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV Multicenter Trial to Evaluate Real-world Pharmacoeconomics of Crizotinib and Its Companion Diagnostic Test in Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC) Patients

NCT02228421 is registered in ClinicalTrials.gov with PeriPharm as lead sponsor.

NCT NCT02228421
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02228421 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV Multicenter Trial to Evaluate Real-world Pharmacoeconomics of Crizotinib and Its Companion Diagnostic Test in Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC) Patients
Lead sponsor
PeriPharm
Phase
Observational
Overall status
Terminated
Start date
February 28, 2015
Completion date
March 31, 2020
Enrollment
29 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer metastatic